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Decreased low density lipoprotein receptor function and mRNA levels
in lymphocytes from uremic patients. The mechanisms by which renal
failure causes hyperlipoproteinemia remain unclear. To investigate the
potential role of the low-density lipoprotein (LDL) receptor in lipopro-
tein metabolism in uremia we measured LDL receptor function in
peripheral blood mononuclear cells (PBMC) from uremic patients and
control subjects using a functional assay in which proliferation of
lectin-stimulated PBMC in the presence of lovastatin was dependent
upon internalization of exogenous cholesterol via a functional LDL
receptor. The amount of LDL required to reverse 50% of lovastatin-
induced inhibition of proliferation in PBMC from uremic patients was
significantly greater (3.6 1.8 tgIml, N = 33, P < 0.05) than controls,
(1.99 0.6 g/ml, N = 37). Abnormal LDL receptor function in four
uremic patients normalized following renal transplantation. To investi-
gate the molecular basis for LDL receptor dysfunction, we directly
quantitated LDL receptor messenger RNA (mRNA) in PBMC from
uremic patients and control subjects using a ribonuclease protection
assay. LDL receptor mRNA expression in uremic patients was 0.42
0.08 (N = 10), significantly lower (P < 0.015) than in normal subjects,
0.71 0.08(N = 14). These data suggest that an acquired defect in LDL
receptor function in PBMC from uremic patients exists which may be
due to decreased LDL receptor expression. These abnormalities, if
present in other tissues, could contribute to the aberrant lipoprotein
metabolism which is a consistent feature of uremia.
Hyperlipidemia is a common metabolic complication of
chronic renal failure. Significant elevations of serum triglycer-
ides [I] and cholesterol [2], as well as the appearance of
abnormal lipoproteins such as /3-VLDL [3], lipoprotein remnant
particles [4], and triglyceride-enriched LDL are frequently
observed in these patients and appears to be independent of the
length of hemodialysis [1, 5]. Such lipid abnormalities have
been identified as significant risk factors for the development of
atherosclerosis [6], as well as other adverse clinical sequelae
such as hyperlipidemic pancreatitis [7]. The hyperlipoprotein-
emia associated with chronic renal failure may be the critical
risk factor which places these patients at high risk for develop-
ing severe generalized atherosclerotic cardiovascular disease
[8—11]. In this regard, accelerated atherosclerosis and coronary
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vascular disease are considered major factors limiting long-term
survival in patients with renal failure [6]. Moreover, animal
studies suggest that hyperlipidemia may also be a major factor
contributing to the progression of renal disease, regardless of
the initial insult. Indeed, the end stage lesion, glomeruloscle-
rosis, bears a remarkable resemblance to atherosclerosis [12—
14].
While many theories have been postulated to explain the
etiology of uremic hyperlipoproteinemia [15], the mechanisms
by which renal failure alters lipoprotein metabolism remain
unclear. The low density lipoprotein (LDL) receptor is a critical
determinant of the regulation of lipid metabolism, and dysfunc-
tion of the LDL receptor is the primary cause of several
clinically significant dyslipoproteinemias [16]. Recent studies in
guinea pigs have suggested that uremia is associated with an
abnormality in hepatic LDL receptor function and cholesterol
synthesis [17, 18]. To date however, such studies have not been
conducted in uremic human subjects. We have therefore inves-
tigated LDL receptor function and LDL receptor mRNA levels
in peripheral blood mononuclear cells (PBMC) from uremic
patients and healthy controls using a recently developed assay
of LDL receptor function [19], and a highly sensitive and
specific ribonuclease protection assay.
Methods
Subjects
The study was approved by the Committee for the Protection
of Human Subjects of the University of Texas Medical School
at Houston. Informed consent was obtained from each subject.
Thirty-three patients with uremia treated with either conserva-
tive management, hemodialysis, or peritoneal dialysis were
studied. The clinical characteristics of these patients are listed
in Tables 1 and 2. None of the patients was taking any
medications known to affect serum lipoprotein levels. Four
subjects were studied on two occasions at different levels of
renal function or during treatment with different dialysis mo-
dalities. Four patients were studied before and at least one
month after renal transplantation at the time when maintenance
immunosuppression with prednisone and cyclosporin A had
been instituted [20]. Thirty-seven healthy subjects, all but two
of whom were adults, served as controls. Informed consent was
obtained from all subjects.
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7 to 69 years
27.2 16 years
Peritoneal dialysis (11)
Hemodialysis (19)
Conservative management (3)
Focal segmental glomerulosclerosis (7)
Glomerulonephritis (4)
Diabetes mellitus (3)
Hypertension (3)
Familial juvenile nephronophthisis (2)
Cystinosis (I)
Obstructive uropathy (I)
Recurrent pyelonephritis (1)
Etiology obscure (11)
75.6 25 (N = 28)
9.35 3.4 (N = 31)
______
The study population for the mRNA assay consisted of a
population of 10 of the uremic patients studied above (6 males
and 4 females, age 32.2 20.2 years) at various clinical degrees
of uremia (mean duration of hemodialysis was 48 39 months),
and 14 clinically healthy individuals served as controls (7 males
and 7 females, age 28.9 7,3 years).
Blood from the uremic subjects was obtained at the beginning
of dialysis, before heparin administration. Serum cholesterol
and triglyceride levels, blood urea nitrogen (BUN), and creat-
mine were determined by standard methods in our clinical
chemistry laboratory. LDL levels were calculated by the stan-
dard Fredrickson formula [211. Dialysis efficiency was assessed
by pre-dialysis BUN in the hemodialysis patients [22], or by
steady state creatinine levels in the peritoneal dialysis patients
[231.
Isolation of peripheral blood mononuclear cells and low
density lipoproteins
Ten to fifteen milliliters of heparinized blood were obtained
from patients and control subjects. Peripheral blood mononu-
clear cells (PBMC) were isolated by centrifugation over a layer
of Ficoll-Hypaque, and were thoroughly washed. PBMC were
pipetted into plastic microtiter plates at i0 cells per well in
RPMI 1640 supplemented with L-glutamine, penicillin, strepto-
mycin, and 1% (vol/vol) lipoprotein poor plasma (LPP) obtained
from ultracentrifugation of AB human plasma at a density of
1.25 g!ml. The cholesterol content of LPP was <10 mg/dl as
determined by a standard colorimetric assay (Sigma Chemical
Company, St. Louis, Missouri, USA). LDL was isolated by
sequential flotation of plasma at a density of 1.006 to 1.063 g!ml
[241, and dialyzed against phosphate-buffered saline. LDL
concentration was expressed as its protein content determined
by standard protein determinations [251.
Assay of LDL receptor function
Accurate quantitation of LDL receptors on freshly-isolated
peripheral mononuclear cells by ligand binding techniques is
difficult because of the low level of LDL receptor expression in
non-dividing cells [26]. However, when PBMC are stimulated
to grow in the presence of lovastatin, an inhibitor of cellular
cholesterol synthesis, cellular proliferation becomes totally
dependent upon the internalization of LDL by functional LDL
Controls Patients
TC mg/dl 189 25.4(N=5)
210 68
(N=30)
TG mg/dI 94 38(N=4) 288
166
(N=30)
LDL mg/dl ill 20(N=5)
106 53
(N= 10)
HDL mgldl 57.8 14.5(N=5)
36.7 10.7
(N=8)
receptors; hence LDL receptors are maximally expressed and
easily assayed [191.
PBMC were stimulated with phytohemagglutinin (PHA) (Dif-
co) 1/1000, and cultured in triplicate in the presence of I to 80
tg/m1 LDL. PBMC cultured in the absence of LDL and PHA
served as a control for spontaneous blastogenesis. For each
concentration of LDL, PBMC were grown in the presence of
0.5 M lovastatin dissolved in dimethyl sulfoxide (DMSO), or
DMSO alone as controls (final DMSO concentration/well was
0.2%). To assess the specificity of the inhibition of cholesterol
synthesis produced by lovastatin and the viability of PBMC in
culture, additional control and uremic cells were treated with 10
mM mevalonic acid in lieu of LDL [19]. To determine the
relative sensitivity of uremic PBMC to lovastatin, dose re-
sponse studies were performed using lovastatin concentrations
of 0.1 to 5.0 .tM. Cell viability was determined by trypan blue
exclusion. Mevalonic acid was prepared by saponification of
mevalonic acid lactone (Sigma Chemicals) with 0.5 N NaOH
followed by neutralization with 1 N HCI to a final pH of 7.0.
PBMC were incubated in 5% carbon dioxide and air at 37°C
for four days, and were then pulsed with tritiated thymidine
(Amersham, 5 Ci/mmol) for 18 hours. After labeling, PBMC
were harvested on glass fiber filters and assayed by scintillation
counting to measure incorporation of label into newly synthe-
sized DNA. At each LDL concentration, percent inhibition was
calculated as the difference in counts-per-minute (CPM) be-
tween the means of the DMSO control and the lovastatin-
treated PBMC by the formula:
[I — (cpm with lovastatin/cpm with DMSO alone)] x 100
Fresh PBMC from normal subjects were included in each set
of incubations as additional controls to monitor the proper
functioning of the assay.
Preparation of RNA from HL6O cells and peripheral blood
mononuclear cells
A human promyelocytic cell line, HL6O, was maintained in
RPMI 1640 medium (Hazleton, Lenexa, Kansas, USA) contain-
ing penicillin (100 U/ml) and streptomycin (100 j.gIml). In some
experiments HL6O cells were treated with 25-hydroxycholes-
terol (Steraloids, Wilton, New Hampshire, USA) dissolved in
ethanol. Approximately 10 x 106 HL6O cells or 20 to 40 x 106
PBMC were extracted with 5 M guanidinium thiocyanate (Fluka
Chemical Corp., Ronkonkoma, New York), 25 m sodium
citrate, 100 mrt p-mercaptoethanol, 17 mtt sodium n-lauryl
Table 1. Clinical characteristics of the uremic patients
Age range
Average age
Dialysis modality (N)
Diagnosis (N)
Mean BUN mg/dl
Mean creatinine mg/d!
Table 2. Biochemical parameters for controls and patients
Abbreviations are: TC, total cholesterol; TG, total triglycerides;
LDL, low density lipoprotein; HDL, high density lipoprotein. Each
value is presented as the mean standard deviation.
1240 Portinan et al: LDL receptor function and mRNA in uremia
sarcosine. Total cellular RNA was isolated by centrifugation at
80,000 x g for 18 hours at 22°C through a 5.7 M cesium chloride
cushion (Schwartz/Mann Biotech, Cleveland, Ohio, USA) [27].
Total extracted RNA was quantitated by spectrophotometry at
A260nm and stored in water treated with diethylpyrocarbonate
(Sigma Chemicals).
PlasmId constructions
The human LDL receptor clone HUMLDL(316) consists of a
316 base-pair (bp) fragment (Pvu H endonuclease digested
fragment of pTZI) from a full length human LDLr eDNA [28],
provided by Dr. D.W. Russell (U.T. Southwestern Medical
Ctr., Dallas, Texas, USA), and subcloned into the plasmid
pGEM-3 (Promega, Madison, Wisconsin, USA). This fragment
contains 220 bp of the 5'-end of the LDL receptor beginning
with the adenosine in the initiator methionine, and is a highly
conserved region that encodes for part of the ligand-binding
domain of the LDL receptor [29], with an additional 96 bp of
bacterial sequence linked 5' to the LDL receptor sequences.
As an internal standard, a human fibroblast cytoplasmic
/3-actin clone pHFJ3A(455) comprised of a 455 bp fragment from
a pBR322 plasmid vector (produced by digestion with Eco RI
and Rsa I endonueleases of pHFBA-3'UT) containing the last
460 bp of the human fibroblast f3-actin [30] was constructed.
The insert consists of 140 bp corresponding to nucleotides
+3480 to +3620 of the 3'-untranslated region, and is highly
conserved and specific for cytoplasmic /3-actin and does not
cross react with other cellular actins [31, 32].
Ribonuclease protection assay of LDL receptor inRNA
Single-stranded antisense RNA probes complementary to the
LDL receptor and f3-actin mRNA were obtained by first digest-
ing the LDL receptor and /3-actin subclones with Eco RI and
Mse I endonucleases, respectively. Labeled RNA probes were
synthesized from linearized templates with SP6 polymerase
(Boehringer-Mannheim, Indianapolis, Indiana, USA) in the
presence of 100 pCi of 32P-UTP (800 Ci/mmol, Amersham,
Arlington Heights, Illinois, USA) as described by the manufac-
turer (Promega, Madison, Wisconsin, USA) with sufficient
unlabeled UTP to achieve 11.4 M final UTP concentration for
LDL receptor probe and 21 /LM for the /3-actin probe. Probe
synthesis was carried out at 37°C for 45 minutes. Transcripts
were precipitated with 2.7 M ammonium acetate, 48.8 ig!ml
glycogen, and 3 x (vol/vol) ethanol and resuspended in depc-
H2O. The LDL receptor probe was 365 bases and /3-actin probe
was 165 bases in length. In the presence of a complementary
RNA these probes yield protected fragments of 220 bases (LDL
receptor) and 140 bases (/3-actin).
The RNAse protection assay was a modification of an earlier
published procedure [33]. Total RNA (10 g) was co-precip-
itated with both 32P-labeled antisense LDL receptor and f3-actin
probes (2.5 to 5.0 x l0 cpm) in the presence of 3 x (vol/vol)
ethanol, 4 g glycogen, and 0.2 M NaCI. The precipitate was
resuspended in a hybridization buffer (80% deionized form-
amide, 620 mrt NaCI, 3 mM PIPES, and 0.3 mM EDTA),
denatured at 95°C for five minutes, and then incubated over-
night at 55°C. RNAse A digestion of the unprotected RNA was
performed by adding 37.8 zg/ml RNAse A (Boehringer Mann-
helm, 50 U/mg) in buffer(l0 mrvi Tris HCI, pH 8.0; 5 mrt EDTA;
200 mi NaCI; and 100 mivi LiCI) to the hybridization solution,
0 1 3 51020 4080M.A
LDL concentration per well, tg/ml
Fig. I. LDL receptorfunction assay. The percent inhibition of PBMC
proliferation by lovastatin was determined at increasing concentrations
of LDL. The control subjects' mean values 5EM (N = 37) are
represented at each concentration by the open bars, and the uremic
patients' (N = 33) by the solid bars. The solid horizontal line represents
zero inhibition, that is, the point where the lovastatin inhibition has
been completely reversed by LDL. (* <0.001)
and incubating at 33°C for 60 minutes. The digestion was
terminated by adding SDS (0.35%), 86.7 g/ml proteinase K
(Boehringer Mannheim, 20 U/mg), and incubating at 37°C for 15
minutes. The samples were then phenol:chloroform-extracted,
ethanol-precipitated in the presence of 20 tg of glycogen, and
fractionated by electrophoresis on 8 M urea, 5% denaturing
polyacrylamide gels. After electrophoresis, gels were dried and
exposed to Kodak XAR film at room temperature with intensi-
fying screens. Autoradiographs were analyzed by laser densit-
ometry and bands corresponding to LDL receptor and /3-actin
mRNAs were quantitated. Results presented are expressed as
the ratio of LDL receptor mRNA//3-actin mRNA to normalize
for any differences in sample loading or hybridization effi-
ciency.
Statistical analysis
The Student's t-test with Bonferroni correction was used to
compare percent inhibition between groups; P < 0.005 was
considered statistically significant [34]. Differences in LDL
concentrations, BUN, creatinine, and lipoprotein levels be-
tween groups were measured by a two-tailed Student's t-test; P
< 0.05 was considered statistically significant. Correlation
between clinical parameters with assay results was measured
by logistic regression analysis. Levels of cellular LDL receptor
mRNA were reported as the mean SEM, and the significance
of differences in levels was determined by unpaired 1-test, with
significance defined as P < 0.05. Correlation between mRNA
levels and biochemical parameters from uremic patients was
calculated by Pearson product moment correlation.
Results
LDL receptor function assay in control and
hypercholeslerolemic subjects
Addition of LDL to peripheral blood mononuclear cells from
the control subjects reversed the lovastatin-mediated inhibition
of proliferation at concentrations less than 10 j.g/ml (Fig. 1).
The slight inhibition of cellular proliferation noted at LDL
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Table 3. Sensitivity of patient and control cells to inhibition by
lovastatin
% Inhibition
Lovastatin Uremic Normal
p.M N=2 N=2
0.1 59.4 58.3
0.5 78.6 75.1
1.0 76.5 74.5
2.0 85.3 92.4
5.0 89.1 90.0
50,000 cells/well were cultured in complete media with 1% LPP, PHA
1/1000 in the presence of increasing concentrations of lovastatin, and %
inhibition calculated as described in the text.
concentrations of 80 j.g!ml in both patient and control cells was
likely due to the direct cellular toxicity of high LDL concentra-
tions [35]. In the control subjects the mean LDLSØ, that is, the
concentration of LDL required to reverse 50% of the lovastatin
inhibition, was 1.99 0.6 p.g/ml. In initial experiments PBMC
from three patients with documented heterozygous familial
hypercholesterolemia, the LDLS0 was greater than 3.00 tg/ml;
in PBMC from a patient with homozygous familial hypercho-
lesterolemia even the highest concentration of LDL could not
reverse lovastatin-mediated inhibition (data not shown). These
results are in accord with previously published values [361, and
demonstrate that the assay accurately detects differences in
PBMC LDL receptor function.
LDL receptor junction assay in uremic patients
Cells from uremic patients demonstrated significant inhibition
of proliferation in the assay (Fig. 1). The mean LDLSØ in the
uremic subjects was 3.6 1.7 p.g/ml, which was significantly
higher than the controls (P < 0.00001). Moreover, the percent
inhibition in the uremic patients was statistically different from
control subjects at each concentration of LDL. Cells from both
normal and uremic patients proliferated equally well in the
presence of mevalonic acid (Fig. 1); hence, the abnormal
proliferation of the uremic cells was not a consequence of an
intrinsic cellular defect. Furthermore, uremic and control
PBMC were identical in their sensitivity to different concentra-
tions of lovastatin (Table 3). These findings suggest that the
LDL receptor does not function normaJly in PBMC from
uremic patients.
Normalization ofLDL receptor function jllowing renal
transplantation
LDL receptor function was studied in four uremic patients
who underwent renal transplantation. The pre-transplantation
mean LDL5Ø of these patients was 5.77 3.7 jsg/ml. However,
when re-studied at least one month after transplantation, the
mean LDL50 of the group had fallen to 1.98 0.42 g/ml, and
relatively low LDL concentrations were able to completely
abolish lovastatin inhibition of PBMC proliferation (Fig. 2).
These observations suggest that LDL receptor dysfunction
associated with renal failure is reversible, and may rapidly
improve with resolution of the uremic state. One patient with
refractory nephrotic syndrome due to focal segmental glomer-
ulosclerosis had an LDL5() of 2.7 p.g./ml. After nephrectomy and
treatment with peritoneal dialysis, the LDL50 increased to 4.8
LOL concentration per well p.g/ml
Fig. 2. LDL receptor function assay ion four patients beforeand after
renal transplantation. The percent inhibition of PBMC proliferation by
lovastatin was determined at increasing concentrations of LDL. Results
are expressed as mean SEM pre-transplantation (open circles) and
post-transplantation (closed circles).
p.g/ml, and even the highest concentrations of LDL were unable
to abolish lovastatin inhibition of PBMC proliferation, as pre-
viously observed with the other uremic patients, This observa-
tion suggests that deterioration of renal function may be asso-
ciated with worsening of LDL receptor function.
Validation of RNA probes and the RIVAase protection assay
A dose-response analysis of the protection of total cellular
RNA against RNAse digestion by LDL receptor and /3-actin
RNA probes was performed to establish the linearity of the
assay. Increasing amounts of RNA extracted from HL6O cells
were hybridized with LDL receptor and /3-actin RNA probes,
digested with RNAse A, and analyzed by electrophoresis and
autoradiography. With increasing amounts of RNA, a progres-
sive increase in the LDL receptor and /3-actin hybridization
signals was observed on the autoradiograph (Fig. 3). Laser
densitometry of the autoradiograph established that a linear
response of the hybridization signal was obtained with both
probes upon increasing RNA mass. The correlation coefficient
was greater than 0.99 for the LDL signal and 0.98 for the f3-actin
signal (Fig. 4). Even with a total RNA mass of 30 p.g (more than
3 times the amount used in standard RNase protection assays),
the response was still linear; hence under these assay condi-
tions there is probe excess even at 30 p.g of total RNA. Standard
assay conditions therefore employed 10 p.g of total RNA per
sample.
To establish that the assay was sensitive to changes in
cellular LDL receptor mRNA, LDL receptor mRNA was
measured in HL6O cells treated with 25-hydroxycholesterol.
The addition of 25-hydroxycholesterol (24 hrs treatment with
0.0625 jig/mI) to HL6O cells produced a 47% decrease in LDL
receptor mRNA relative to untreated cells (data not shown), in
agreement with the known down-regulation of the LDL recep-
tor and its mRNA by this oxysterol [37].
RNAase protection assay of LDL receptor mRNA in PBMC
from uremic patients and controls
To investigate the molecular basis for the LDL receptor
dysfunction observed in the uremic subjects, we quantitated
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Fig. 3. Dose-response analysis of HL6O total cellular RNA with LDL receptor and 13-actin RNA antisense probes in a ribonuclease protection
assay. Increasing amounts of HL6O total cellular RNA was RNase protected with LDL receptor and /3-actin RNA probes as described in Methods.
The figure indicates the position of the protected mRNA fragments (220 bases for LDL receptor mRNA; 140 bases for /3-actin RNA) relative to
radiolabeled Hae III endonuclease digested X-174 DNA used as size markers.
RNA, p.g
Fig. 4. Demonstration of dose-response and linearity of the RIVase
protection assay system used in experiments. Laser densitometry was
performed on autoradiograph from the HL6O RNA dose-response
experiment. Relative optical absorbance area-under-the-curve for the
LDL receptor and j3-actin RNA probes are plotted as a function of
increasing HL6O total cellular RNA mass. Symbols are: (0) /3-actin, r>
0.98; (I) < DLr, r > 0.99.
LDL receptor mRNA in freshly collected PBMC from uremic
patients and control subjects with the RNAase protection
assay. As indicated by the LDL receptor hybridization signal at
220 bases and the /3-actin signal at 140 bases, a marked decrease
in LDL receptor mRNA was observed in uremic patients
relative to the controls (Fig. 5). The LDL receptor mRNA
signal, normalized to the /3-actin mRNA signal, was 0.42 0.08
(N = 10) for the uremic patients, versus 0.71 0.09 (N = 14) for
the controls (Fig. 6). This represents a 40% relative decrease in
LDL receptor mRNA, which was highly significant at P <
0.015. No alteration in j3-actin mRNA level was observed in the
uremic patients compared to controls. These data suggest that a
significant reduction in LDL receptor mRNA was present in
PBMC from uremic patients.
Associations between assay results and clinical parameters
The mean serum cholesterol level in the uremic subjects was
210 68 mg/dl (mean SD); 72% of the patients had elevated
levels for their age [38] (Table 2). The mean serum triglyceride
levels in uremic subjects was 288 166 mgldl (Table 2), and
75% of the patients had levels which were elevated for their age
[38]. Regression analysis revealed no correlation between the
LDL5Ø or LDL receptor mRNA levels and measures of renal
function (that is, blood urea nitrogen or serum creatinine) or
dialysis efficiency (that is, pre-dialysis BUN in the patients
receiving hemodialysis or steady state creatinine in patients
treated with peritoneal dialysis). Nor was there a significant
correlation between these tests and serum total cholesterol,
triglycerides, LDL or HDL concentrations. This was not unex-
pected as previously noted [19, 39]. Examination of different
dialysis modalities revealed that LDL50 and serum cholesterol
levels were significantly higher in patients treated by peritoneal
dialysis than by hemodialysis.
Discussion
The mechanisms which cause altered lipoprotein metabolism
in renal disease have not been well delineated. Although
abnormalities of lipoprotein lipase [40, 41], hepatic lipase [42]
and lecithin-cholesterol acyltransferase [43] in uremia have
been described, few studies have addressed the function of the
LDL receptor. Our data establish that LDL receptor function
as measured by this assay in PBMC from uremic patients is
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Fig. 5. Autoradiograph of RNase protection assay of PBMC RNA from a uremic patient and two controls. A total cellular RNA mass of lOg from
each sample was hybridized with the LDL receptor and /3-actin antisense RNA probes and RNase A protected fragments were subjected to 8 M
urea, 5% polyacrylamide gel electrophoresis. The LDL receptor protected band = 220 bases and the 3-actin protected band = 140 bases.
Fig. 6. LDL receptor rnRNA:f3-actin mRNA index for a larger study of
uremic patients and healthy controls. RNase protection assays were
performed on 10 g of PBMC RNA from uremic patients (N = 10) and
controls (N = 14). LDL receptor and 3-actin mRNA levels were
quantitated from autoradiographs by laser densitometry. LDL receptor
mRNA level was normalized with /3-actin to correct for any differences
in RNA mass from sample to sample, and an L:A inde s is shown for
uremic patients and controls.
depressed. The level of dysfunction in this assay is similar to
that seen in patients with familial hypercholesterolemia and
other lipoprotein disorders associated with decreased lipopro-
tein clearance but by different mechanisms. Moreover, the
LDL receptor dysfunction appears to be reversible, as it is
reversed by renal transplantation, which suggests a transient
down-regulation by physiological factors.
The receptor dysfunction observed in uremic patients was
associated with a significant reduction of PBMC LDL receptor
mRNA when compared to healthy controls. This decrease
could be due to any number of factors, such as uremic factors
that either specifically inhibit transcription of LDL receptor
mRNA, or modulate the amount of activity of critical factors
required for LDL receptor gene transcription. Uremia could
also reduce LDL receptor mRNA stability and/or accelerate
degradation, thereby leading to decreased steady-state LDL
receptor mRNA levels. Another possible mechanism for ure-
mic-induced alteration in LDL receptor gene expression is a
uremic effect on mitogenic stimulation of LDL receptor gene
expression. It has been shown that mitogens can increase LDL
receptor mRNA levels in human lymphocytes [44]. Uremic
conditions may somehow interfere with normal mitogenic sig-
naling in these lymphocytes. Interestingly, Cuthbert and Lipsky
found that an oxygenated sterol could down-regulate LDL
receptor gene expression equally in both mitogenic stimulated
and control lymphocytes [441.
While it has proved difficult to directly measure LDL recep-
tor protein on PBMC from uremic subjects, all studies to date
suggest that reduced levels of LDL receptor mRNA should
result in diminished synthesis and cellular expression of LDL
receptor protein.
Several other candidate mechanisms for the observed recep-
tor dysfunction must also be considered. It is possible that the
depressed receptor function is a consequence of a global
alteration in PBMC cholesterol synthesis secondary to non-
specific toxic effects of uremia. This is unlikely, however, as the
addition of mevalonic acid completely restored the proliferative
response in the uremic PBMCs. Structural alteration of the
LDL molecule or the LDL receptor in the uremic environment
could alter the affinity of their interaction, or disrupt the process
of LDL internalization and digestion [45]. However, in our
studies we utilized normal LDL isolated from healthy donors,
and the incubation conditions for the PBMC used in our assay
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is sufficiently long that newly synthesized LDL receptors would
likely have been cycled to the PBMC surface. One could also
speculate that a mechanism unrelated to LDL receptor activity
could account for the observed functional defect. If this were
the case, however, mevalonate should not have been able to
restore normal proliferation to the uremic cells.
It is possible that differences in the lymphocyte/monocyte
ratio of the cells isolated from the patients and controls could
influence the response to lovastatin or phytohemagglutinin.
However, in the assay of LDL receptor function, each patient
serves as his own control, that is, inhibition of cellular prolif-
eration is calculated relative to PBMC grown in optimal condi-
tions. Thus the effect of differences in mononuclear cell sub-
population distribution upon the specificity of the assay for
inhibition of LDL receptor function should be minimized. The
possibility that uremic PBMC are more sensitive to lovastatin
was made less plausible by the identical behavior of uremic and
control PBMC in the dose-response studies.
A final consideration is that our findings may be a conse-
quence of cellular toxicity of chemically modified forms of
cholesterol. The decreased reductive capacity of uremic serum
[46] may generate oxidatively modified sterols, such as 25-
hydroxycholesterol, 7-ketocholesterol or 4-hydroxynonenal,
some of which have been identified in LDL isolated from
uremic patients [47]. Some of these oxysterols are 100 times
more potent than LDL in inhibiting LDL receptor biosynthesis
[37, 48], and prolonged exposure of PBMC to oxysterols in vivo
could account for the decreased LDL receptor function and
receptor mRNA levels observed in this study. However, since
uremic PBMC grown with LDL in the absence of lovastatin
proliferated normally, it seems unlikely that uremic PBMC
directly generated oxysterols in vitro.
The elevations in serum triglycerides and moderate eleva-
tions in cholesterol in renal failure patients are directly associ-
ated with the degree of uremia [49], yet we observed no
relationship between PBMC LDL receptor function or mRNA
and serum lipids, lipoprotein levels, or crude measures of
uremic severity in our patients. Significant correlations could
have been obscured by the fact that the receptor function assay
measures the maximum expression of PBMC LDL receptors,
and not their receptor status immediately upon removal from
the uremic milieu, or by the insensitivity of pre-dialysis BUN
and steady-state creatinine levels to the clinical severity of
uremia. Further, the LDL levels in these patients were not
directly measured and the hypertriglyceridemia can lead to an
overestimation of VLDL cholesterol by this formula and sub-
sequently, a falsely low LDL fraction [21]. Uremia is associated
with an increase in abnormal lipoproteins including particles
which are -VLDL-like in that they contain both apolipopro-
teins B and E and are typically triglyceride rich with some
cholesterol [4]. The uremic LDL particle itself is triglyceride
enriched. These particles are cleared, in part by the LDL (BIE)
receptor. Thus a decrease in the LDL receptor funciton would
be expected to produce an increase in both triglycerides and to
a lesser extent cholesterol. There was also great variability in
cholesterol and triglyceride levels in uremic patients based on
variable nutritional status of some of the patients as evidenced
by the large standard deviations of these values (Table 2).
Nonetheless, improvement in patients' clinical status post
transplantation was associated with a decrease in LDL5Ø, and
deterioration after nephrectomy was associated with increased
LDL5Ø.
At this time we can only speculate upon the relationship
between LDL receptor dysfunction and the genesis of hyper-
lipidemia in renal failure. If other cells, such as endothelial
cells, hepatocytes, and macrophages, manifested LDL receptor
abnormalities similar to those seen in the PBMC, then intravas-
cular LDL clearance would be decreased and hypercholester-
olemia would ensue. Delayed clearance of LDL would also
increase its exposure time to uremic plasma, and encourage the
formation of oxidized species of LDL which have been impli-
cated in foam cell formation [50]. Since the LDL receptor, or
B/E receptor, also recognizes very low density lipoproteins
(VLDL), reduced hepatic LDL receptor function could lead to
the accumulation of VLDL, and VLDL remnants which, as
they contain a high percentage of triglycerides, would lead to
hypertriglyceridemia. Finally, reduced hepatic uptake of
VLDL, VLDL remnants, and LDL would result in the up-
regulation of hepatic cholesterol biosynthesis, as has been
documented by Shapiro [18].
The increasing evidence that uremic hyperlipidemia consti-
tutes a significant risk factor for accelerated atherosclerosis and
progression of renal failure mandates an aggressive approach to
the management of this condition. Nonetheless, therapy for
these patients, especially in the pediatric population where
early intervention may be most productive, is problematic.
Dietary modification of cholesterol intake is extremely difficult
because of other dietary restrictions imposed on these patients
and, by itself, is rarely sufficient to control serum lipid levels.
Although fibric acids are effective [51, 52], their renal excretion
and the risk of serious myopathy limit their use. Recently it was
demonstrated that depressed LDL receptor function in the
lymphocytes of heterozygous FH patients was normalized by
treatment with hypolipidemic drugs [36]. Pharmacotherapy
with an HMG-CoA reductase inhibitor which enhances LDL
receptor function may be useful in uremic patients. Probucol,
which has been shown to decrease oxysterol production 153],
could potentially be effective in treating uremic hyperlipidemia
by preventing LDL receptor mRNA down-regulation.
In summary, we have demonstrated abnormal LDL receptor
function in PBMC's in uremic patients, which is reversed by
renal transplantation. We have further documented a concom-
itant reduction in lymphocyte LDL receptor mRNA levels in
uremic patients compared to controls, suggesting that down-
regulation of the transcription of LDL receptor mRNA or
accelerated mRNA degradation could be the cause of this
phenomena. Further investigation of LDL receptor function in
renal disease will contribute to the elucidation of the causes of
uremic hyperlipidemia and may hasten the development of
effective therapy to retard the progression of renal failure and
atherosclerosis in uremia.
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